GID4 and sarcoma: No significant differences were observed in the mOS between GID4 altered and GID4 WT advanced sarcoma patients in either cohort (CGDB cohort: mOS of 5.6 months [3.0-NA] vs 9.8 months [7.4–12.2], p = 0.4; Australian cohort: mOS of NA months [19.7-NA] vs 41.3 months [30.9–59.9], p = 0.6, Fig. S6).